Syntekabio Inc.’s Post

In the high-risk world of drug development, staying ahead requires more than just innovation—it demands transformative technology. 💡 STB LaunchPad from Syntekabio is designed to revolutionize your drug discovery process. With our powerful independent supercomputing enabling our proprietary AI platform, we streamline your pipeline to deliver results faster and more efficiently. 🔍 Why choose STB LaunchPad? •Accelerated Discovery: Benefit from rapid identification of promising drug candidates, reducing time to market. You will have access to over 10 billion compounds as well as 1,400 in vitro/in vivo compatible drug targets •Enhanced Precision: Utilize our DeepMatcher® AI platform for highly accurate drug discovery across diverse therapeutic areas. DeepMatcher® utilizes Flexible Molecular Docking (FMD) to continuously capture protein-ligand interactions/poses •Broad Coverage: We cover more than 70% of human diseases •Proven Results: Providing you with superior outcomes achieved through our proprietary discovery platform and a network of successful industry collaborations •Save costs: Compounds validated before you make significant R&D investment Discover how our cutting-edge technology can transform your research and development 👉 https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

Two innovative companies backed by Qiming - Ailomics Therapeutics and Yanyin Technology have deepened their partnership. The Ailomics team has started utilizing the molecular biology module, yanMolecule, of the Yanyin Smart Research Cloud developed by Yanyin Technology. The Yanyin Smart Research Cloud aims to enhance the work efficiency of researchers through AI technology, accelerating the empowering process of innovative drug development. It's dedicated to transforming the biopharmaceutical R&D process from traditional, inefficient, paper-based management to a digital, efficient management model. Ailomics Therapeutics focuses on diseases with significant clinical needs.Through its pioneering computational biology platform, Ailomics dives deep into analyzing multiomics data from patients, finding new mechanisms and drug targets propelling disease progression, leading to the creation of innovative medications. #QMportfolio #QMhealthcare #Ailomics #YanyinTech #InnovativeMedicine #DrugResearch #QimingVenturePartners #Collaboration #digitalization

It’s not often that a reporter takes the time to ask about what drives your team to innovate and why at Juvena we decided to focus on secreted proteins. We are grateful to David Wild for the opportunity to reflect on how our CEO Dr. Hanadie Yousef's interests in biopharma innovation are shaping our approach to developing regenerative therapeutics for chronic and rare conditions. If you want to learn more about why we’re so excited to advance our pipeline and partner with large pharma to solve some of the greatest unmet needs of our time, check out the article linked below (subscription required). Here’s an excerpt from the article: "Juvena Therapeutics employs advanced computing to map the 4,000 proteins secreted by human cells. Through an AI-enabled platform, the company can identify potential protein-disease relationships and engineer medicines accordingly. By integrating AI, robotics and other cutting-edge technologies, Juvena accelerates preclinical screening and advances promising candidates to in-house clinical development. The platform has already generated an asset ready for clinical trials for Myotonic Dystrophy, a preclinical asset in obesity, and over 50 promising leads." #womeninbiotech #womeninlifescience #longevity https://lnkd.in/gnk7QaBd

I’m pleased to announce that I’ll be presenting at BIOVIA Live! 🎤 Join me as I explore the groundbreaking deep learning and AI-based tools within Discovery Studio that are revolutionizing biologics research. In my talk, I’ll highlight: 🔹 OpenFold and AlphaFold Multimer for precise protein structure prediction 🔹 RFDiffusion for designing innovative protein scaffolds 🔹 Protein MPNN for efficient sequence optimization Additionally, I’ll showcase how our AI-enhanced solutions for antibody humanization are streamlining therapeutic design, and the deep learning-driven paratope prediction that provides unparalleled accuracy in epitope identification. These advancements are empowering researchers with unprecedented capabilities to accelerate and refine the biologics development process. I can’t wait to share insights and explore the future of biologics research together! See you there! 🚀 #BIOVIALive #Biologics #AI #DeepLearning #ResearchInnovation

Today, Archon Biosciences announced $20 million in seed financing led by Madrona and shared our vision for the future of drug development!    We’ve built a completely novel class of biologics, Antibody Cages (AbCs) designed to unlock powerful therapeutic targets beyond the reach of existing modalities and to better treat disease. AbCs integrate the unparalleled binding properties of antibodies into a boundless set of AI-generated nanostructures that have never existed in nature. Precise control over AbC structures provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold standard for biologic medicines.      Learn more in our press release here: https://lnkd.in/eTJxYNuk    To see AbCs in action and learn more about how Archon is applying generative protein design to improve human health, visit our website at https://www.archon.bio/     #biotech #antibodies #AI #ComputationalProteinDesign #AbC 

I’m very excited about the emergence of Archon Biosciences today!  We’ve been working 'in stealth' for over a year (James Lazarovits and George Ueda for 5+ years before that…!) to translate this incredible technology into powerful biotherapeutics unlike any other – both in structure and capability.    I remember the first time I read about computationally designed de novo proteins – yes, that’s a mouthful – and the Institute for Protein Design, University of Washington circa 2018 (after vaguely hearing about fold.it many years before that) – it seemed incredible.  Fast forward to last year when I met Jamie and George – I can confirm they are incredible (the science, the platform and the team – now Archon Bio!).  By the way, so did The Nobel Prize committee, which recognized computational protein design with the 2024 Nobel Prize in Chemistry (read more about that on our website at archon.bio)     Having started in biotechnology decades ago working on the amazing new promise of antibodies, I’m super excited about Archon’s potential. From previously ‘intractable’ MoAs (e.g. soluble autonomous agonism) to qualitatively differential potency, to significantly enhancing existing powerful antibody-based medicines – we’re excited to make it happen.     Finally, we’re interested in advancing medicines from this transformative (modular) platform to patients as fast as possible beyond our own pipeline – if you can imagine new possibilities with your antibody-based drugs, reach out and let’s chat!     #biotech #antibodies #AI #ComputationalProteinDesign #AbC #AntibodyCage 

📰 Unlock the Future of Drug Discovery with Syntekabio’s Exclusive Newsletter! 📰 Step into the future with Syntekabio, where AI meets drug discovery in ways never before imagined. Our innovative approaches are not just keeping up with the industry—they’re setting new standards. Subscribe today to keep your finger on the pulse of cutting-edge developments that could change the way you approach R&D. 🌟 Why Subscribe? ➡ Exclusive Insights: Gain insider access to our cutting-edge programs, including our game-changing offer where we invest in your success, with Develop Now, Pay Later. ➡ In-Depth Articles: Dive into comprehensive articles that explore the latest breakthroughs and trends in AI and drug discovery. ➡ Early Access to New Opportunities: Stay ahead with the first look at new offerings, including our complimentary feasibility testing and customized AI solutions to accelerate your R&D. 📩 Don’t miss this chance to enhance your expertise and stay at the forefront of innovation. Subscribe to our newsletter today and be part of the future of drug discovery. https://lnkd.in/eXC4EuiF #AI #DrugDiscovery #healthcareinnovation #Pharma #machinelearning #oncology

Discover how Lifebit is driving efficiency in drug discovery with our latest module. By harnessing external expertise and cutting-edge technologies, we're working to accelerate the path to novel therapeutics. Explore the insights in our latest white paper: https://bit.ly/3w7mQOU #DrugDiscoveryWorkflows #Pharma #Lifebit

𝐅𝐫𝐨𝐦 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐭𝐨 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠: 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐑𝐚𝐫𝐞 𝐚𝐧𝐝 𝐎𝐫𝐩𝐡𝐚𝐧 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬 Orphan drug development follows a process similar to that of drugs for larger patient populations, but with specific challenges. These include limited natural history data and early biomarkers, the lack of appropriate in vitro/in vivo models, and the absence of suitable clinical outcomes or surrogate endpoints for clinical trials. Overcoming these hurdles requires innovative approaches and leveraging diverse data sources during orphan drug development. At Syngene, we are dedicated to addressing the unique challenges of rare and orphan diseases. Our comprehensive solutions span the entire spectrum of services from early discovery to manufacturing. This includes our computational and data sciences services, discovery biology services, preclinical safety assessment, process development, and manufacturing. Learn more: link in comments section 🔗 #drugdevelopment #drugdiscovery #rarediseases 

Revolutionizing Healthcare: Machine Learning in Drug Discovery The pharmaceutical industry is undergoing a transformative shift, thanks to machine learning! Traditional drug discovery methods are time-consuming, costly, and often yield limited success rates. Machine learning algorithms analyze vast amounts of molecular data, identifying relationships between: Structural properties Pharmacokinetic properties Biological activity Key applications include: Predictive modeling Virtual screening Lead optimization Success stories: Atomwise: Used ML to discover a new compound for Ebola treatment Insilico Medicine: Developed AI-generated compounds for cancer treatment Challenges and future directions: Data quality Interpretability Integration Join the conversation! Share your thoughts on machine learning in drug discovery. #MachineLearning #DrugDiscovery #ComputationalAnalysis #PharmaceuticalIndustry #DigitalHealth #HealthcareInnovation #AIinDrugDiscovery